Clinical Trial Update: A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update reporting results for subcutaneous daratumumab versus active monitoring in participants with high-risk smoldering multiple myeloma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smoldering Multiple Myeloma

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Smoldering Multiple Myeloma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-12-23